Verastem, Inc. (VSTM)

AI-Powered SEC Filing Analysis

Insider Trading Filed: 2026-01-23

Key Insights

The CEO Dan Paterson has received a grant of 213,785 restricted stock units (RSUs), representing a significant equity award to align his interests with shareholders.
The RSUs vest over a 3-year period, indicating a long-term focus and commitment from the CEO to the company's success.
The insider ownership of the CEO has increased to 613,889 shares, suggesting strong alignment between management and shareholders.

Insider Trading Filed: 2026-01-23

Key Insights

The reporting person, Daniel Calkins, was granted 16,665 restricted stock units (RSUs) as part of his compensation as the Chief Financial Officer of Verastem, Inc.
The RSUs vest over a 3-year period, with 33.3% of the RSUs vesting on each of the first three anniversaries of January 21, 2026, provided Calkins remains employed by the company.
This grant of RSUs increases Calkins' beneficial ownership of Verastem's common stock to 121,384 shares, indicating the company's commitment to incentivizing and retaining its key executive.

Insider Trading Filed: 2026-01-14

Key Insights

The Chief Financial Officer of Verastem, Inc. (VSTM) sold 5,039 shares of common stock on January 12, 2026 for $7.16 per share, reducing his total beneficial ownership to 104,719 shares.
The sale was made to satisfy statutory withholding requirements in connection with the vesting of restricted stock units, indicating a routine transaction related to executive compensation.
The transaction volume and timing do not suggest any significant changes in the CFO's confidence or the company's outlook, as the sale represents a small fraction of his total holdings.

Insider Trading Filed: 2026-01-14

Key Insights

The reporting person, Dan Paterson, who is the President and CEO of Verastem, Inc., sold 10,321 shares of the company's common stock on January 12, 2026, likely to satisfy statutory withholding requirements related to the vesting of restricted stock units.
Paterson's ownership of Verastem's common stock decreased from 410,425 shares to 400,104 shares following the reported transaction.
The sale was made pursuant to a 10b5-1 trading plan, indicating it was part of a pre-arranged strategy and not based on material, non-public information.

Insider Trading Filed: 2026-01-08

Key Insights

Michael Kauffman, the President of Development at Verastem, Inc., has been granted a stock option to purchase 200,000 shares of common stock at an exercise price of $6.88 per share, vesting over a three-year period.
The stock option grant suggests that Verastem is incentivizing its key executive to maintain a long-term focus on the company's development and growth.
Insider buying, such as this stock option grant, can signal management's confidence in the company's future prospects.

Current Report Filed: 2026-01-08

Key Insights

Verastem, Inc. has posted an updated corporate presentation on its website, providing investors with the latest information about the company.
The filing does not indicate any major changes or events, suggesting the update is a routine disclosure rather than a significant development.
Investors should review the updated presentation to stay informed about Verastem's business and any potential future developments.

Current Report Filed: 2025-12-31

Key Insights

Verastem, Inc. has discontinued the RAMP 203 clinical trial in advanced KRAS G12C-mutated non-small cell lung cancer to focus resources on the development of VS-7375, an oral KRAS G12D inhibitor, in advanced NSCLC and other solid tumors.
The discontinued RAMP 203 trial had mixed results, with the doublet combination showing a 40% overall response rate in treatment-naive patients but only 9.5% in previously treated patients, and the triplet combination showing a 50% response rate in treatment-naive patients and 36% tumor reduction in previously treated patients.
The decision to discontinue RAMP 203 reflects the evolving treatment landscape for KRAS G12C inhibitors and Verastem's strategic prioritization of programs with the greatest potential impact for patients with advanced lung cancer.

Get real-time filing analysis in the app

Download on the App Store

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.